Bell Potter notes that Neuren has released an update on Acadia's sales and its expected royalties. It said: ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Rett syndrome hits hard and early, but with Neuren’s Daybue and Neurotech’s cannabis-based NTI164 building steam, the fight ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Here are a couple of ASX 200 shares that analysts are tipping to rise strongly from current levels. Here's what you need to ...

Dual-listed across the Nasdaq composite and the ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as sales of its flagship drug DAYBUE jump +14% on Q2 2024. Listen ...

Let's see what awaits Aussie investors during today's session. The post 5 things to watch on the ASX 200 on Tuesday appeared ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...